An expert summarizes that Tara-002, a novel immunotherapy derived from Streptococcus pyogenes, is showing promising results in a phase 2 trial for non–muscle-invasive bladder cancer—particularly in ...

Data showed that fracture risk rises briefly after menopausal hormone therapy discontinuation, then falls below never-users.

In a recent interview, Andrea Pezzella, MD, URPS, FACOG, of Southern Urogynecology Wellness & Aesthetics in West Columbia, South Carolina, shared insights on the newly FDA-approved Neuspera integrated ...

Metastasis-directed radiotherapy without systemic therapy (MRWS) demonstrated promising efficacy with manageable safety in patients with oligometastatic clear cell renal cell carcinoma (ccRCC), ...

According to Song, novel aspiration technologies are reshaping not only care delivery, but also long-term treatment outcomes. The emergence of new aspiration devices for stone disease has been a ...

The expanded labeling would enable the use of flibanserin to treat hypoactive sexual desire disorder in postmenopausal women.

The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.

"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.

Panelists discuss how the treatment paradigm for androgen deprivation therapy is evolving from traditional injectable GnRH agonists to include oral GnRH antagonists like relugolix, which offer more ...

In this interview, Daniel D. Joyce, MD, MS, assistant professor of urology at Vanderbilt University Medical Center in Nashville, Tennessee, discusses the economic and clinical considerations of using ...

The American Medical Association (AMA) has announced a new category III CPT code for the use of Avvio Medical’s Enhanced Lithotripsy System (ELS) for acoustic enhancer microbubble cavitation (AEMC) ...